Forward Pharma A/S provided an update on the Company's strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and License Agreement with Biogen. Consistent with the focus on executing on the intellectual property strategy and the planned timeline for conclusion of ongoing research and development activities, Executive Vice Presidents Rupert Sandbrink and Andrzej Stano will be leaving the Company in the third quarter of 2017, and Chief Financial Officer Joel Sendek has left the company, effective April 30, 2017. Certain non-executive roles primarily in research and development will be made redundant, with the goal of reducing the total number of full-time employees to below seven.